These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 9664195)

  • 1. New drugs in the management of the irritable bowel syndrome.
    Farthing MJ
    Drugs; 1998 Jul; 56(1):11-21. PubMed ID: 9664195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
    Farthing MJ
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Functional colonic diseases: from physiopathology to pharmacology].
    Bardou M
    Rev Med Interne; 1999 Feb; 20(2):151-7. PubMed ID: 10227093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
    Scarpignato C; Pelosini I
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F; Tonini M
    Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug treatment options for irritable bowel syndrome: managing for success.
    Dunphy RC; Verne GN
    Drugs Aging; 2001; 18(3):201-11. PubMed ID: 11302287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome.
    Delvaux M; Louvel D; Lagier E; Scherrer B; Abitbol JL; Frexinos J
    Gastroenterology; 1999 Jan; 116(1):38-45. PubMed ID: 9869600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug therapy options for patients with irritable bowel syndrome.
    Talley NJ
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug treatment of the irritable bowel syndrome.
    Pattee PL; Thompson WG
    Drugs; 1992 Aug; 44(2):200-6. PubMed ID: 1382014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
    Maxton DG; Morris J; Whorwell PJ
    Aliment Pharmacol Ther; 1996 Aug; 10(4):595-9. PubMed ID: 8853764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
    Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
    Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic therapy for the irritable bowel syndrome.
    Talley NJ
    Am J Gastroenterol; 2003 Apr; 98(4):750-8. PubMed ID: 12738451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of drug treatment in irritable bowel syndrome.
    Talley NJ
    Br J Clin Pharmacol; 2003 Oct; 56(4):362-9. PubMed ID: 12968980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging treatments for irritable bowel syndrome.
    Ahn J; Ehrenpreis ED
    Expert Opin Pharmacother; 2002 Jan; 3(1):9-21. PubMed ID: 11772329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron).
    Goldberg PA; Kamm MA; Setti-Carraro P; van der Sijp JR; Roth C
    Digestion; 1996; 57(6):478-83. PubMed ID: 8913711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic approach to the patient with irritable bowel syndrome.
    Camilleri M
    Am J Med; 1999 Nov; 107(5A):27S-32S. PubMed ID: 10588170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Functional intestinal disorders and quality of life].
    Chassany O; Bergmann JF
    Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C54-62. PubMed ID: 11787380
    [No Abstract]   [Full Text] [Related]  

  • 18. [Visceral sensitivity and functional bowel disorders: physiopathological role and therapeutic perspectives].
    Delvaux M; Frexinos J
    Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C42-53. PubMed ID: 11787379
    [No Abstract]   [Full Text] [Related]  

  • 19. 5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
    Kishibayashi N; Miwa Y; Hayashi H; Ishii A; Ichikawa S; Nonaka H; Yokoyama T; Suzuki F
    J Med Chem; 1993 Oct; 36(22):3286-92. PubMed ID: 8230119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
    Steadman CJ; Talley NJ; Phillips SF; Zinsmeister AR
    Mayo Clin Proc; 1992 Aug; 67(8):732-8. PubMed ID: 1434911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.